Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Retained Earnings (2020 - 2023)

Candel Therapeutics' Retained Earnings history spans 4 years, with the latest figure at -$125.9 million for Q3 2023.

  • For Q3 2023, Retained Earnings fell 33.94% year-over-year to -$125.9 million; the TTM value through Sep 2023 reached -$125.9 million, down 33.94%, while the annual FY2022 figure was -$99.1 million, 23.41% down from the prior year.
  • Retained Earnings for Q3 2023 was -$125.9 million at Candel Therapeutics, down from -$117.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$44.2 million in Q4 2020 and bottomed at -$125.9 million in Q3 2023.
  • The 4-year median for Retained Earnings is -$85.3 million (2022), against an average of -$89.4 million.
  • The largest annual shift saw Retained Earnings plummeted 81.78% in 2021 before it dropped 14.79% in 2022.
  • A 4-year view of Retained Earnings shows it stood at -$44.2 million in 2020, then tumbled by 81.78% to -$80.3 million in 2021, then decreased by 23.41% to -$99.1 million in 2022, then fell by 27.06% to -$125.9 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Retained Earnings are -$125.9 million (Q3 2023), -$117.5 million (Q2 2023), and -$107.9 million (Q1 2023).